Boston Scientific Corporation (BSX) : Endurant Capital Management Lp scooped up 250,600 additional shares in Boston Scientific Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 526,698 shares of Boston Scientific Corporation which is valued at $12,582,815.Boston Scientific Corporation makes up approximately 3.57% of Endurant Capital Management Lp’s portfolio.
Other Hedge Funds, Including , D.a. Davidson reduced its stake in BSX by selling 4,067 shares or 38.82% in the most recent quarter. The Hedge Fund company now holds 6,410 shares of BSX which is valued at $153,135. Vsr Financial Services sold out all of its stake in BSX during the most recent quarter. The investment firm sold 10,098 shares of BSX which is valued $241,241.Bnp Paribas Investment Partners S.a. boosted its stake in BSX in the latest quarter, The investment management firm added 586,919 additional shares and now holds a total of 2,348,291 shares of Boston Scientific Corporation which is valued at $56,030,223. Boston Scientific Corporation makes up approx 0.48% of Bnp Paribas Investment Partners S.a.’s portfolio.Dekabank Deutsche Girozentrale boosted its stake in BSX in the latest quarter, The investment management firm added 70,280 additional shares and now holds a total of 365,324 shares of Boston Scientific Corporation which is valued at $8,818,921. Boston Scientific Corporation makes up approx 0.10% of Dekabank Deutsche Girozentrale’s portfolio.Standard Life Investments Ltd reduced its stake in BSX by selling 286,634 shares or 1.44% in the most recent quarter. The Hedge Fund company now holds 19,686,347 shares of BSX which is valued at $465,778,970. Boston Scientific Corporation makes up approx 2.04% of Standard Life Investments Ltd’s portfolio.
Boston Scientific Corporation opened for trading at $24.07 and hit $24.35 on the upside on Thursday, eventually ending the session at $24.33, with a gain of 2.14% or 0.51 points. The heightened volatility saw the trading volume jump to 91,15,567 shares. Company has a market cap of $33,107 M.
On the company’s financial health, Boston Scientific Corporation reported $0.27 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.27. The company had revenue of $2126.00 million for the quarter, compared to analysts expectations of $2044.88 million. The company’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.
Many Wall Street Analysts have commented on Boston Scientific Corporation. Boston Scientific Corporation was Upgraded by Argus to ” Buy” on Sep 1, 2016. Company shares were Reiterated by Wedbush on Jul 29, 2016 to “Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $23 .Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 28 from a previous price target of $26 .
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.